Artiva Biotherapeutics, Inc. Finance Lease, Principal Payments
Artiva Biotherapeutics, Inc. (ARTV) reported Finance Lease, Principal Payments of $45.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. finance lease, principal payments for the quarter ending 2026-06-30 was $12.00K, a 63.64% decline year-over-year.
- Artiva Biotherapeutics, Inc. finance lease, principal payments for the quarter ending 2026-03-31 was $33.00K, a 0.00% change year-over-year.
- Artiva Biotherapeutics, Inc. finance lease, principal payments for the quarter ending 2025-12-31 was $34.00K, a 3.03% increase year-over-year.
- Artiva Biotherapeutics, Inc. finance lease, principal payments for the quarter ending 2025-09-30 was $32.00K, a 15.79% decline year-over-year.
- Artiva Biotherapeutics, Inc. finance lease, principal payments for fiscal 2025 was $132.00K, a 11.41% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. finance lease, principal payments for fiscal 2024 was $149.00K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $45.00K 10-Q · filed 2026-08-06 | $79.00K derived: sum of 3 quarters · filed 2026-08-06 | $111.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $33.00K 10-Q · filed 2026-05-08 | $67.00K derived: sum of 2 quarters · filed 2026-05-08 | $99.00K derived: sum of 3 quarters · filed 2026-05-08 | $132.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $66.00K derived: sum of 2 quarters · filed 2026-03-10 | $99.00K derived: sum of 3 quarters · filed 2026-08-06 | $132.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $65.00K derived: sum of 2 quarters · filed 2026-08-06 | $98.00K 10-Q · filed 2025-11-12 | $131.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $66.00K 10-Q · filed 2026-08-06 | $99.00K derived: sum of 3 quarters · filed 2026-08-06 | $137.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $33.00K 10-Q · filed 2026-05-08 | $66.00K derived: sum of 2 quarters · filed 2026-05-08 | $104.00K derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $71.00K derived: sum of 2 quarters · filed 2026-03-10 | $149.00K 10-K · filed 2026-03-10 | |
| 2024-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $116.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $78.00K 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |